The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects

AIMS: LCZ696 (angiotensin receptor neprilysin inhibitor) is a novel drug developed for the treatment of heart failure with reduced ejection fraction. Neprilysin is one of multiple enzymes degrading amyloid‐β (Aβ). Its inhibition may increase Aβ levels. The potential exists that treatment of LCZ696,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Clin Pharmacol
Egile Nagusiak: Langenickel, Thomas H., Tsubouchi, Chiaki, Ayalasomayajula, Surya, Pal, Parasar, Valentin, Marie‐Anne, Hinder, Markus, Jhee, Stanford, Gevorkyan, Hakop, Rajman, Iris
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2016
Gaiak:
Pharmacodynamics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4834603/
https://ncbi.nlm.nih.gov/pubmed/26663387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12861
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak